



## Xeris to Participate in Upcoming Investor Conferences

August 22, 2024

CHICAGO--(BUSINESS WIRE)--Aug. 22, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

- 2024 Wells Fargo Healthcare Conference, Boston, MA
  - Meetings only on September 4, 2024
- H.C. Wainwright 26<sup>th</sup> Annual Global Investor Conference, New York, NY
  - Meetings and fireside chat on September 10, 2024 at 3:30pm ET
- 2024 Cantor Global Healthcare Conference, New York, NY
  - Meetings only on September 18, 2024

Please check with each conference sponsor to arrange 1x1 meetings.

Webcast information for the fireside chat will be available at <https://xerispharma.com/investor-relations>.

### About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit [www.xerispharma.com](http://www.xerispharma.com), or follow Xeris on [Twitter](#), [LinkedIn](#) or [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240822640280/en/): <https://www.businesswire.com/news/home/20240822640280/en/>

### Investor Contact

Allison Wey  
Senior Vice President, Investor Relations and Corporate Communications  
[awey@xerispharma.com](mailto:awey@xerispharma.com)

Source: Xeris Biopharma Holdings, Inc.